Esperion Therap (NASDAQ: ESPR) reported Q2 EPS of ($0.60), in-line with the analyst estimate of ($0.60).

“Top-line results are expected in early October from our Phase 2b ETC-1002-008 clinical trial in statin intolerant patients. Results from our 2-year carcinogenicity studies are anticipated late in the fourth quarter, while top-line results from two additional Phase 2 studies are expected in the first half of 2015,” said Tim M. Mayleben, president and chief executive officer of Esperion. “We believe that ETC-1002 is the right drug in development for the treatment of patients with hypercholesterolemia and a history of statin intolerance. This is a patient population that is increasingly recognized as deserving of more effective oral therapy options.”

For earnings history and earnings-related data on Esperion Therap (ESPR) click here.